HC Wainwright Reaffirms Buy Rating for ANI Pharmaceuticals (NASDAQ:ANIP)

HC Wainwright reaffirmed their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) in a report published on Monday morning,Benzinga reports. The brokerage currently has a $94.00 price objective on the specialty pharmaceutical company's stock.

Other analysts have also recently issued research reports about the stock. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They issued an "overweight" rating and a $68.00 target price on the stock. Truist Financial increased their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research note on Tuesday, October 22nd. StockNews.com lowered shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Finally, Raymond James increased their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research note on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $77.33.

ANI Pharmaceuticals Stock Up 0.5 %

Shares of ANIP traded up $0.30 during mid-day trading on Monday, hitting $61.74. 324,743 shares of the company's stock were exchanged, compared to its average volume of 216,177. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -112.25 and a beta of 0.71. ANI Pharmaceuticals has a fifty-two week low of $48.20 and a fifty-two week high of $70.81. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. The stock's 50-day moving average is $58.61 and its 200-day moving average is $61.47.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to analysts' expectations of $144.37 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.05 earnings per share. On average, sell-side analysts anticipate that ANI Pharmaceuticals will post 3.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently modified their holdings of ANIP. Texas Permanent School Fund Corp lifted its holdings in shares of ANI Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company's stock worth $912,000 after purchasing an additional 172 shares during the period. Louisiana State Employees Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company's stock worth $490,000 after purchasing an additional 200 shares during the period. Arizona State Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 4.7% during the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company's stock worth $299,000 after purchasing an additional 211 shares during the period. Simplicity Wealth LLC lifted its holdings in shares of ANI Pharmaceuticals by 3.5% during the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company's stock worth $429,000 after purchasing an additional 227 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company's stock worth $1,118,000 after purchasing an additional 233 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.